Imperial Capital analyst Jeff Kessler upgraded Axon Enterprise to Outperform from In-Line with an unchanged price target of $68. The analyst has a positive outlook on the company's recurring revenue business model and future profitability for fiscal 2020. In addition, Taser's leading market position, brand awareness and business model give Axon a "significant advantage" over competitors in using the cash flow from its less-lethal weaponry business to fund a software-as-a-service leadership in the developing business of online forensics and evidence management, Kessler tells investors in a research note.